KalshiScience and Technology
Will the FDA approve camizestrant for advanced breast cancer?
camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation
Ends Jul 1, 2026
Bet NowDisclosure
18+ only. Event contracts carry significant risk and are not suitable for everyone, you can lose the entire amount you commit. Not available in all jurisdictions; restrictions and eligibility requirements apply.
- Before Jul 1, 20264.2K VOL.——
- Before Oct 1, 202618.3K VOL.Yes 99%No 1%99¢
- Before Jan 1, 20275.1K VOL.Yes 99%No 1%99¢
- Before Jan 1, 20281.3K VOL.Yes 94%No 6%94¢
Rules Summary
If the FDA approves camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation for marketing before Jul 1, 2026, then the market resolves to Yes.
Timeline and Payout
- Opened
- May 14, 2026, 2:00 AM
- Closes
- Jul 1, 2026, 3:59 AM
- Pays out
- 0.5 hours after close
Series KXFDAAPPROVE · Event KXFDAAPPROVE-CAM · Market KXFDAAPPROVE-CAM-26JUL01